Aminocyclohexylsulfonamides: Discovery of metabolically stable α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 22, 2007, Pages 6123-6128

  Chiu, George ^a   Li, Shengjian ^a   Cai, Hong ^a   Connolly, Peter J ^a   Peng, Sean ^a   Stauber, Kathe ^a   Pulito, Virginia ^a   Liu, Jingchun ^a   Middleton, Steven A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

1 blockers; 1a 1d adrenergic receptors; 1a 1d adrenoceptor selective antagonists; BPH LUTS

Indexed keywords

(PHENYLPIPERAZINYL)CYCLOHEXYLSULFONAMIDE DERIVATIVE; (PHENYLPIPERIDINYL)CYCLOHEXYLSULFONAMIDE DERIVATIVE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; SULFONAMIDE; TAMSULOSIN; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; LOWER URINARY TRACT SYMPTOM; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; BINDING, COMPETITIVE; CYCLOHEXYLAMINES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; MALE; MICROSOMES; MOLECULAR STRUCTURE; PROSTATIC HYPERPLASIA; SULFONAMIDES;

EID: 35148838062     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.051     Document Type: Article

References (26)

1. Rosini M., Bolognesi M., Giardina D., Minarini A., Tumiatti V., and Melchiorre C. Curr. Top. Med. Chem. 7 (2007) 147
2. Michelotti G.A., and Schwinn D.A. Curr. Urol. Rep. 5 (2004) 258
3. Cutis N.J. Urology 62 (2003) 34
4. Lowe F.C. Clin. Ther. 26 (2004) 1701
5. Muramatsu I., Suzuki F., Tanaka T., Yamamoto H., and Morishima S. J. Pharm. Soc. Jpn. 126 (2006) 187
6. Bruno J.F., Whittaker J., Song J., and Berelowitz M. Biochem. Biophys. Res. Commun. 179 (1991) 1485
7. Ramarao C.S., Kincade Denker J.M., Perez D.M., Galvin R.J., Riek R.P., and Graham R.M. J. Biol. Chem. 267 (1992) 21936
8. Hirasawa A., Horie K., Tanaka T., Takagaki K., Murai M., Yano J., and Tsujimoto G. Biochem. Biophys. Res. Commun. 195 (1993) 902
9. Forray C., Bard J.A., Wetzel J., Chiu G., Shapiro E., Tang R., LePor H., Hartig P.R., Weinshank R.L., Branchek T.A., and Gluchowski C. Mol. Pharmacol. 45 (1994) 703
10. Wetzel J.M., Miao S.W., Forray C., Borden L.A., Branchek T.A., and Gluchowski C. J. Med. Chem. 38 (1995) 1579
11. Wong W.C., Chiu G., Wetzel J.M., et al. J. Med. Chem. 41 (1998) 2643
12. Lagu B., Tian D., Chiu G., Nagarathram D., Fang J., Shen Q., Forray C., Ransom R.W., Chang R.S.L., Vyas K.P., Zhang K., and Gluchowski C. Bioorg. Med. Chem. Lett. 10 (2000) 175
13. Blue, D. R., Jr.; Grino, P. B.; Jung, D. T.; et al. [abstract]. In Proceedings of the Fifth International Consultation on BPH, June 25, 2000.
14. Ilampel C., Dolber P.C., Smith M.P., et al. J. Urol. 167 (2002) 1513
15. Gu B., Reiter J.P., Schwinn D.A., et al. J. Urol. 172 (2004) 758
16. Smith M.S., Scharnbra U.M., Wilson K.H., Page S.O., and Schwinn D.A. Brain Res. Mol. Brain Res. 63 (1999) 254
17. Cavalli A., Lattion A.L., Hummler E., et al. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 11589
18. Schwinn D.A., Price D.T., and Narayan P. Mayo Clin. Proc. 79 (2004) 1423
19. Roehrborn C.G., and Schwinn D. J. Urol. 171 (2004) 1029
20. Sarma P.K.S., Tiwari A., and Pal A. Expert Opin. Ther. Patents 15 (2005) 1333
21. Daniels D.V., Gever J.R., Jasper J.R., Kava M.S., et al. Eur. J. Pharmacol. 370 (1999) 337
22. Lowe F.C. Clin. Ther. 26 (2004) 1701
23. Chiu G., Li S., Connolly P.J., Pulito V., Liu J., and Middleton S.A. Bioorg. Med. Chem. Lett. 17 (2007) 3292
24. Chiu G., Li S., Connolly P.J., Pulito V., Liu J., and Middleton S.A. Bioorg. Med. Chem. Lett. 17 (2007) 3930
25. f values are the trans isomers. This assignment is based on the NMR pattern of similar (piperazinyl)-cyclohexylsulfonamide compounds with known cis or trans configurations.
26. 3) 1.1-1.4 (m, 4H), 1.65 (m, 2H),1.8-2.0 (m, 6H), 2.30 (m, 3H), 2.93 (m, 3H), 3.04 (m, 1H), 3.92 (s, 3H), 3.94 (s, 3H), 4.33 (q, J = 14.8 Hz, 2H), 4.80 (d, J = 8.1 Hz, NH, 1H), 6.7-7.5 (m, 7H) MS: 557 (M+1).